Lung cancer is the second-most commonly diagnosed cancer in both men and women, and is the leading cause of cancer deaths in Canada. Rearrangement of the Anaplastic Lymphoma Kinase (ALK) gene drives the development of about 5% of non–small cell lung cancers (NSCLC). Inhibitors of ALK can effectively delay progression of these malignancies and ar...